Edwards Lifesciences Corp (EW)vsMyomo Inc (MYO)
EW
Edwards Lifesciences Corp
$85.96
-1.70%
HEALTHCARE · Cap: $49.01B
MYO
Myomo Inc
$1.28
+15.91%
HEALTHCARE · Cap: $49.46M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 15196% more annual revenue ($6.30B vs $41.21M). EW leads profitability with a 17.4% profit margin vs -36.7%. EW earns a higher WallStSmart Score of 61/100 (C+).
EW
Buy61
out of 100
Grade: C+
MYO
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.7%
Fair Value
$253.29
Current Price
$85.96
$167.33 discount
Intrinsic value data unavailable for MYO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.2%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
16.7% revenue growth
No standout strengths identified
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
2.9% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bull Case : MYO
MYO has a balanced fundamental profile.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.
Bear Case : MYO
The primary concerns for MYO are Revenue Growth, EPS Growth, Market Cap. Debt-to-equity of 2.11 is elevated, increasing financial risk.
Key Dynamics to Monitor
EW profiles as a growth stock while MYO is a turnaround play — different risk/reward profiles.
MYO carries more volatility with a beta of 1.46 — expect wider price swings.
EW is growing revenue faster at 16.7% — sustainability is the question.
MYO generates stronger free cash flow (-3M), providing more financial flexibility.
Bottom Line
EW scores higher overall (61/100 vs 23/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Myomo Inc
HEALTHCARE · MEDICAL DEVICES · USA
Myomo, Inc., a portable medical robotics company, designs, develops and produces myoelectric braces for people with neuromuscular disorders in the United States. The company is headquartered in Boston, Massachusetts.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?